Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02663518 · OUTCOME

Part 1: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors · Source last updated 2024-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Part 1: Week 1 end of infusion (EOI)

What was measured

CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells .

Analysis population: This outcome measure was not analyzed since CD47 data for Part 1 was not collected as the assay was not set up when enrolling the Part 1 participants. Hence, no participants evaluable for this outcome measure.

Groups in this outcome

Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg

Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.

Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg

Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.

Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg

Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.

Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg

Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg0
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg0
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg0
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      0
    units
    Participants
description
CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells .
groups
  1. description
    Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
    id
    OG000
    title
    Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg
  2. description
    Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
    id
    OG001
    title
    Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg
  3. description
    Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
    id
    OG002
    title
    Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg
  4. description
    Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
    id
    OG003
    title
    Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg
population Description
This outcome measure was not analyzed since CD47 data for Part 1 was not collected as the assay was not set up when enrolling the Part 1 participants. Hence, no participants evaluable for this outcome measure.
reporting Status
POSTED
time Frame
Part 1: Week 1 end of infusion (EOI)
title
Part 1: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice